Form 4 for IBRX ImmunityBio, Inc.

Accepted 2023-01-04 00:00:00 ET · period of report 2022-12-31 · accession 0001326110-23-000004 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-01-04	2022-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	F - Tax	$5.07	-4,273	144.4K	-3%	-$21.7K
D	2023-01-04	2022-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	M - OptEx	$0.00	+8,620	148.7K	+6%	$0
D	2023-01-04	2022-12-31	IBRX	Adcock Richard	CEO, Pres, Dir	M - OptEx	$0.00	-8,620	155.2K	-5%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2022-12-31	F	D	4,273	$5.07	144,441	D	—	—	(F1) On December 31, 2022, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2022 was the settlement price used to calculate the shares withheld.
2	Common	Common Stock	2022-12-31	M	A	8,620	$0.00	148,714	D	—	—
3	Derivative	Restricted Stock Units	2022-12-31	M	D	8,620	$0.00	155,180	D	— · — to —	8,620 Common Stock	(F2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F3) Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.